- Published on
KembaraXtra-Medicine – Autoimmune Hepatitis
Autoimmune hepatitis (AIH) is an immune-mediated inflammatory liver disease marked by elevated serum gamma globulins (especially IgG), characteristic circulating autoantibodies, and typical biopsy findings of interface hepatitis with plasma cell–rich inflammation, after other causes of hepatitis have been excluded. There are two main types. Type 1 AIH is the most common worldwide (about 90%) and can occur at any age; it is often associated with antinuclear antibodies (ANA) and/or smooth muscle antibodies (SMA), and sometimes anti–soluble liver antigen (anti-SLA) or anti–liver-pancreas (anti-LP) antibodies. Type 2 AIH is less common (up to 10%), mainly affects children and young adolescents, and is typically associated with anti-LKM-1 or anti-LC1 antibodies, while ANA and SMA are usually absent; it often presents more acutely and may be harder to treat, with frequent relapse requiring long-term maintenance therapy.
AIH is more common in females and can occur across all ethnicities and age groups. In the United States, prevalence is estimated around 31 per 100,000 people, and globally incidence is roughly 0.9 to 2 cases per 100,000 people per year, with prevalence estimates ranging widely. Type 1 AIH has a bimodal peak (around puberty and again in mid-to-late adulthood), while type 2 is more common from ages 2 to 14. AIH accounts for a small but important portion of liver transplants in the U.S. (about 4% to 6%).
The exact cause is unknown, but AIH is thought to result from genetic susceptibility plus an environmental trigger. A leading theory involves a T-cell–mediated immune attack on hepatocytes, possibly related to reduced or dysfunctional regulatory T cells; humoral immunity also appears involved given the range of autoantibodies. Proposed triggers include viral infections (hepatitis A, B, C) and medications (such as minocycline, nitrofurantoin, biologics, and TNF inhibitors). Certain HLA haplotypes are associated with increased risk, including HLA-DR3 and DR4 in type 1 AIH and HLA-DR3 and DR7 in type 2.
Clinical presentation is broad, ranging from asymptomatic liver enzyme elevations to cirrhosis or fulminant liver failure. Symptoms may include fatigue, anorexia, nausea, abdominal pain, pruritus, and arthralgias. Some patients have other autoimmune features such as arthritis, dry mouth, eye irritation (keratoconjunctivitis), vasculitis, or erythema nodosum. Advanced disease can present with hepatosplenomegaly, ascites, peripheral edema, easy bruising/bleeding, and jaundice.
Diagnosis is based on a combination of laboratory evidence of liver injury, elevated IgG or hypergammaglobulinemia, characteristic autoantibodies, and compatible liver histology, while excluding other causes of hepatitis. Both major liver societies (EASL and AASLD) require a liver biopsy to establish diagnosis. Histology is suggestive rather than pathognomonic, with findings such as lymphoplasmacytic infiltrates crossing the limiting plate (interface hepatitis), periportal inflammation/necrosis, rosetting of hepatocytes, and emperipolesis. If cholestatic features are present, primary biliary cholangitis and primary sclerosing cholangitis should be evaluated; MRCP is recommended in adults with cholestatic lab changes and in all children with AIH, with ERCP considered if MRCP is nondiagnostic.
Workup includes history and exam (including screening for other autoimmune diseases), liver function tests and serum gamma globulins/IgG, and autoantibody testing (ANA, SMA/ASMA, anti-LKM, anti-SLA/LP). Aminotransferases are usually elevated (often ALT > AST) and may fluctuate; bilirubin and alkaline phosphatase may be normal or moderately elevated. IgG is elevated in about 90% of patients. Ultrasound is commonly used to rule out obstruction or mass, and MRCP is used when cholestasis suggests overlap disease. Patients with AIH-related cirrhosis should undergo hepatocellular carcinoma surveillance (typically ultrasound and AFP every 6 months).
Treatment includes avoiding alcohol and hepatotoxic medications, and considering liver transplantation for fulminant liver failure or end-stage disease. Steroids are the cornerstone: prednisone/prednisolone is commonly started at 0.5 to 1 mg/kg/day (often up to 60 mg/day) for induction. Azathioprine can be started at the same time or about 2 weeks later (often beginning at 50 mg/day and titrating up to 1 to 2 mg/kg/day depending on response and toxicity). In noncirrhotic AIH, budesonide (6 to 9 mg/day) plus azathioprine can be used to induce and maintain remission with fewer systemic steroid side effects; budesonide should not be used in cirrhosis due to reduced first-pass metabolism and increased systemic effects. Steroids may be avoided or used cautiously in brittle diabetes, uncontrolled hypertension, severe osteopenia, psychosis, or prior severe intolerance, while azathioprine is contraindicated in TPMT deficiency and significant cytopenias. Alternatives for azathioprine intolerance include 6-mercaptopurine and mycophenolate mofetil, and other second-line options (e.g., calcineurin inhibitors, sirolimus/everolimus, rituximab, infliximab) have been used in select refractory cases.
Treatment response is monitored with symptoms and normalization of liver tests, but biopsy activity can lag behind lab improvement by up to 6 months. Because relapse is common after withdrawal (often requiring long-term maintenance therapy), repeat biopsy is often considered before stopping therapy. Persistent interface hepatitis on biopsy is associated with very high relapse risk, and multiple relapses are linked with a higher chance of cirrhosis, so repeated attempts at withdrawal are generally discouraged. Acute severe AIH should be treated early with high-dose corticosteroids, and if there is no improvement within about 7 days, urgent transplant evaluation is recommended; acute liver failure presentations should be evaluated directly for transplantation.
Long-term outlook is generally good with treatment: many patients achieve remission within 18 months to 3 years, but a minority do not respond to standard therapy. Patients with decompensated cirrhosis, acute liver failure, hepatocellular carcinoma, or progression despite therapy should be referred for liver transplant evaluation.
Autoimmune hepatitis (AIH) is an immune-mediated inflammatory liver disease marked by elevated serum gamma globulins (especially IgG), characteristic circulating autoantibodies, and typical biopsy findings of interface hepatitis with plasma cell–rich inflammation, after other causes of hepatitis have been excluded. There are two main types. Type 1 AIH is the most common worldwide (about 90%) and can occur at any age; it is often associated with antinuclear antibodies (ANA) and/or smooth muscle antibodies (SMA), and sometimes anti–soluble liver antigen (anti-SLA) or anti–liver-pancreas (anti-LP) antibodies. Type 2 AIH is less common (up to 10%), mainly affects children and young adolescents, and is typically associated with anti-LKM-1 or anti-LC1 antibodies, while ANA and SMA are usually absent; it often presents more acutely and may be harder to treat, with frequent relapse requiring long-term maintenance therapy.
AIH is more common in females and can occur across all ethnicities and age groups. In the United States, prevalence is estimated around 31 per 100,000 people, and globally incidence is roughly 0.9 to 2 cases per 100,000 people per year, with prevalence estimates ranging widely. Type 1 AIH has a bimodal peak (around puberty and again in mid-to-late adulthood), while type 2 is more common from ages 2 to 14. AIH accounts for a small but important portion of liver transplants in the U.S. (about 4% to 6%).
The exact cause is unknown, but AIH is thought to result from genetic susceptibility plus an environmental trigger. A leading theory involves a T-cell–mediated immune attack on hepatocytes, possibly related to reduced or dysfunctional regulatory T cells; humoral immunity also appears involved given the range of autoantibodies. Proposed triggers include viral infections (hepatitis A, B, C) and medications (such as minocycline, nitrofurantoin, biologics, and TNF inhibitors). Certain HLA haplotypes are associated with increased risk, including HLA-DR3 and DR4 in type 1 AIH and HLA-DR3 and DR7 in type 2.
Clinical presentation is broad, ranging from asymptomatic liver enzyme elevations to cirrhosis or fulminant liver failure. Symptoms may include fatigue, anorexia, nausea, abdominal pain, pruritus, and arthralgias. Some patients have other autoimmune features such as arthritis, dry mouth, eye irritation (keratoconjunctivitis), vasculitis, or erythema nodosum. Advanced disease can present with hepatosplenomegaly, ascites, peripheral edema, easy bruising/bleeding, and jaundice.
Diagnosis is based on a combination of laboratory evidence of liver injury, elevated IgG or hypergammaglobulinemia, characteristic autoantibodies, and compatible liver histology, while excluding other causes of hepatitis. Both major liver societies (EASL and AASLD) require a liver biopsy to establish diagnosis. Histology is suggestive rather than pathognomonic, with findings such as lymphoplasmacytic infiltrates crossing the limiting plate (interface hepatitis), periportal inflammation/necrosis, rosetting of hepatocytes, and emperipolesis. If cholestatic features are present, primary biliary cholangitis and primary sclerosing cholangitis should be evaluated; MRCP is recommended in adults with cholestatic lab changes and in all children with AIH, with ERCP considered if MRCP is nondiagnostic.
Workup includes history and exam (including screening for other autoimmune diseases), liver function tests and serum gamma globulins/IgG, and autoantibody testing (ANA, SMA/ASMA, anti-LKM, anti-SLA/LP). Aminotransferases are usually elevated (often ALT > AST) and may fluctuate; bilirubin and alkaline phosphatase may be normal or moderately elevated. IgG is elevated in about 90% of patients. Ultrasound is commonly used to rule out obstruction or mass, and MRCP is used when cholestasis suggests overlap disease. Patients with AIH-related cirrhosis should undergo hepatocellular carcinoma surveillance (typically ultrasound and AFP every 6 months).
Treatment includes avoiding alcohol and hepatotoxic medications, and considering liver transplantation for fulminant liver failure or end-stage disease. Steroids are the cornerstone: prednisone/prednisolone is commonly started at 0.5 to 1 mg/kg/day (often up to 60 mg/day) for induction. Azathioprine can be started at the same time or about 2 weeks later (often beginning at 50 mg/day and titrating up to 1 to 2 mg/kg/day depending on response and toxicity). In noncirrhotic AIH, budesonide (6 to 9 mg/day) plus azathioprine can be used to induce and maintain remission with fewer systemic steroid side effects; budesonide should not be used in cirrhosis due to reduced first-pass metabolism and increased systemic effects. Steroids may be avoided or used cautiously in brittle diabetes, uncontrolled hypertension, severe osteopenia, psychosis, or prior severe intolerance, while azathioprine is contraindicated in TPMT deficiency and significant cytopenias. Alternatives for azathioprine intolerance include 6-mercaptopurine and mycophenolate mofetil, and other second-line options (e.g., calcineurin inhibitors, sirolimus/everolimus, rituximab, infliximab) have been used in select refractory cases.
Treatment response is monitored with symptoms and normalization of liver tests, but biopsy activity can lag behind lab improvement by up to 6 months. Because relapse is common after withdrawal (often requiring long-term maintenance therapy), repeat biopsy is often considered before stopping therapy. Persistent interface hepatitis on biopsy is associated with very high relapse risk, and multiple relapses are linked with a higher chance of cirrhosis, so repeated attempts at withdrawal are generally discouraged. Acute severe AIH should be treated early with high-dose corticosteroids, and if there is no improvement within about 7 days, urgent transplant evaluation is recommended; acute liver failure presentations should be evaluated directly for transplantation.
Long-term outlook is generally good with treatment: many patients achieve remission within 18 months to 3 years, but a minority do not respond to standard therapy. Patients with decompensated cirrhosis, acute liver failure, hepatocellular carcinoma, or progression despite therapy should be referred for liver transplant evaluation.
- Published on
Emergency and Acute Medicine – Measles
Basics description
Measles, also known as rubeola, is a vaccine-preventable infectious disease that primarily affects children and is characterized by fever, cough, coryza, conjunctivitis, and an erythematous maculopapular rash. Due to widespread immunization, incidence is now low, but outbreaks continue to occur in nonimmunized or underimmunized populations.
Etiology
Measles is caused by the rubeola virus, a morbillivirus in the paramyxovirus family with negative-strand RNA. Humans are the only known reservoir. The virus is highly contagious and transmitted via respiratory droplets or direct contact; therefore, respiratory isolation must be initiated when measles is suspected. Outbreaks are most often associated with lapses in vaccination coverage.
Special populations
During pregnancy, measles infection increases the risk of spontaneous abortion and premature contractions but does not appear to cause congenital malformations. Pregnant patients should not receive MMR or MMRV vaccines. Adults born before 1957 are generally considered immune; however, health care workers should receive vaccination if serologic testing shows negative titers. In pediatrics, routine immunization with MMR or MMRV begins at ≥12 months of age, with a second dose at 4–6 years; catch-up doses must be spaced at least 4 weeks apart.
Diagnosis, signs, and symptoms
After an incubation period of approximately 10–12 days, patients develop a prodrome lasting 1–7 days with fever, malaise, cough, coryza, and conjunctivitis. Koplik spots—small white to grayish-blue lesions on the buccal mucosa—are pathognomonic and appear 1–2 days before the rash, disappearing shortly after rash onset. The classic maculopapular blanching rash develops 3–7 days into illness, beginning on the head and spreading downward. It may become confluent and occasionally petechial, rarely involving the palms and soles. Rash resolution occurs over several days and may be followed by desquamation.
Complications
Respiratory complications are common, with pneumonia occurring in approximately 6% of cases and representing the most frequent cause of death, particularly in immunocompromised patients. Otitis media, sinusitis, and diarrhea are also frequent. Neurologic complications include seizures and encephalitis, which may develop days after rash onset due to postinfectious autoimmune mechanisms. A rare but fatal late complication is subacute sclerosing panencephalitis, occurring years after infection. Cardiovascular complications such as myocarditis or conduction defects are uncommon but may be clinically significant in older adults.
Essential workup and diagnostic testing
Diagnosis is primarily clinical, based on the combination of fever, cough, coryza, conjunctivitis, and characteristic rash. Laboratory confirmation may include measles IgM and IgG serology or PCR for measles RNA. Viral isolation from blood, throat, nasopharynx, or urine is mainly for epidemiologic surveillance. CSF analysis is indicated if encephalitis is suspected, and chest radiography is obtained when pneumonia is a concern.
Differential diagnosis
Conditions to consider include rubella, scarlet fever, infectious mononucleosis, roseola, erythema infectiosum, enteroviral infections, Kawasaki disease, secondary syphilis, toxic shock syndrome, and drug reactions.
Treatment and emergency management
Management is primarily supportive, focusing on antipyretics, hydration, and monitoring for complications. Strict isolation is required. Postexposure prophylaxis for susceptible individuals includes MMR vaccination within 72 hours of exposure or intramuscular immune globulin within 6 days for high-risk contacts such as infants, pregnant patients, and immunocompromised individuals. Oxygenation and airway protection are essential in cases complicated by pneumonia or encephalitis.
Medications
The World Health Organization recommends vitamin A supplementation for children with measles, particularly in areas of deficiency, as it reduces morbidity and mortality. Dosing is age-based and administered once daily for two days.
Disposition and follow-up
Hospital admission is indicated for patients with severe pneumonia, dehydration, encephalitis, SSPE, immunocompromise, or significant comorbidities. Patients are contagious from 4 days before symptom onset until 4 days after rash appearance; immunocompromised individuals may remain contagious longer. Discharge is appropriate for stable patients without complications, with clear instructions on isolation and follow-up.
Pearls and pitfalls
Measles is one of the most contagious infectious diseases, with significant morbidity and mortality despite modern care. Early recognition and respiratory isolation are critical in health care settings. Immunocompromised patients may not develop the classic rash, increasing the risk of missed diagnosis. Vaccination remains the most effective preventive measure.
- Published on
KembaraXtra-Medicine – Methanol Poisoning
Methanol is a colorless, volatile liquid that is rapidly absorbed within 30–60 minutes and metabolized by the liver, with a half-life of approximately 4–8 hours. Methanol itself is relatively nontoxic and produces inebriation similar to ethanol. Toxicity results from its metabolites, formaldehyde and formic acid, which inhibit cytochrome oxidase and disrupt cellular respiration. Formic acid is primarily responsible for severe metabolic acidosis, visual toxicity, and mortality, as it is directly toxic to the retina and optic nerve. Methanol is metabolized in three steps: conversion to formaldehyde by alcohol dehydrogenase, rapid conversion of formaldehyde to formic acid by aldehyde dehydrogenase, and folate-dependent degradation of formic acid to carbon dioxide and water. The first and third steps are rate-limiting.
Common sources of methanol exposure include windshield washer fluid, wood alcohol, carburetor cleaners, fuel antifreeze solutions, formalin, gasoline, paint solvents, household cleaners, Sterno cans, moonshine, model airplane fuel, photocopying fluids, and perfumes. Ingestion may be intentional or accidental, and inhalational exposure can occur with solvent abuse.
Clinical manifestations often begin with gastrointestinal symptoms such as anorexia, nausea, vomiting, and abdominal pain. Central nervous system findings include headache, dizziness, confusion, inebriation, seizures, and coma. Ophthalmologic symptoms are characteristic and include blurry or hazy vision, photophobia, “snowfield” vision, central scotomas, and potentially permanent blindness. Patients may present without a clear ingestion history but instead with an unexplained high anion gap metabolic acidosis and elevated osmol gap. On examination, findings may include tachypnea, altered mental status, optic disc hyperemia or pallor, papilledema, and afferent pupillary defects.
Evaluation requires a careful history of all possible ingestions and attention to visual complaints, along with a funduscopic examination. Essential laboratory tests include arterial blood gas analysis, serum electrolytes, glucose, BUN, creatinine, measured serum osmolality, and serum levels of methanol, ethanol, ethylene glycol, and isopropyl alcohol. The anion gap and osmol gap should be calculated. The osmol gap is most useful early in poisoning, as methanol is osmotically active, whereas its toxic metabolites are not. Importantly, a normal osmol gap does not exclude methanol poisoning, especially in late presenters. Serum methanol levels confirm the diagnosis, though levels may be undetectable late in the course when severe acidosis is present.
Management begins with prompt stabilization of airway, breathing, and circulation, along with administration of dextrose, naloxone, and thiamine for altered mental status. Further absorption is limited by supportive care, as gastric lavage and activated charcoal have limited benefit due to rapid methanol absorption. The cornerstone of treatment is inhibition of alcohol dehydrogenase to prevent formation of toxic metabolites. Fomepizole is the preferred antidote and should be initiated promptly when methanol ingestion is suspected, even before serum levels return. Ethanol infusion is an alternative when fomepizole is unavailable but is associated with significant adverse effects and requires close monitoring.
Hemodialysis plays a critical role by enhancing elimination of methanol and its metabolites and correcting severe acidosis. Indications include visual symptoms, severe or refractory metabolic acidosis, renal failure, ingestion of large amounts of methanol, or serum methanol levels greater than 25 mg/dL. Hemodialysis is continued until methanol levels fall below 25 mg/dL and acidosis resolves. Adjunctive therapy with folic or folinic acid is recommended to enhance metabolism of formic acid. Sodium bicarbonate is used to correct severe acidosis, with the goal of maintaining a normal serum pH.
Patients with significant exposure require hospital admission, often to the intensive care unit, and transfer to a facility with antidote availability and hemodialysis capability if needed. Asymptomatic patients with low methanol levels, normal acid–base status, and stable electrolytes may be considered for discharge. Psychiatric evaluation is important in cases of intentional ingestion. Early recognition and treatment are essential, as delays greatly increase the risk of blindness and death.
Methanol is a colorless, volatile liquid that is rapidly absorbed within 30–60 minutes and metabolized by the liver, with a half-life of approximately 4–8 hours. Methanol itself is relatively nontoxic and produces inebriation similar to ethanol. Toxicity results from its metabolites, formaldehyde and formic acid, which inhibit cytochrome oxidase and disrupt cellular respiration. Formic acid is primarily responsible for severe metabolic acidosis, visual toxicity, and mortality, as it is directly toxic to the retina and optic nerve. Methanol is metabolized in three steps: conversion to formaldehyde by alcohol dehydrogenase, rapid conversion of formaldehyde to formic acid by aldehyde dehydrogenase, and folate-dependent degradation of formic acid to carbon dioxide and water. The first and third steps are rate-limiting.
Common sources of methanol exposure include windshield washer fluid, wood alcohol, carburetor cleaners, fuel antifreeze solutions, formalin, gasoline, paint solvents, household cleaners, Sterno cans, moonshine, model airplane fuel, photocopying fluids, and perfumes. Ingestion may be intentional or accidental, and inhalational exposure can occur with solvent abuse.
Clinical manifestations often begin with gastrointestinal symptoms such as anorexia, nausea, vomiting, and abdominal pain. Central nervous system findings include headache, dizziness, confusion, inebriation, seizures, and coma. Ophthalmologic symptoms are characteristic and include blurry or hazy vision, photophobia, “snowfield” vision, central scotomas, and potentially permanent blindness. Patients may present without a clear ingestion history but instead with an unexplained high anion gap metabolic acidosis and elevated osmol gap. On examination, findings may include tachypnea, altered mental status, optic disc hyperemia or pallor, papilledema, and afferent pupillary defects.
Evaluation requires a careful history of all possible ingestions and attention to visual complaints, along with a funduscopic examination. Essential laboratory tests include arterial blood gas analysis, serum electrolytes, glucose, BUN, creatinine, measured serum osmolality, and serum levels of methanol, ethanol, ethylene glycol, and isopropyl alcohol. The anion gap and osmol gap should be calculated. The osmol gap is most useful early in poisoning, as methanol is osmotically active, whereas its toxic metabolites are not. Importantly, a normal osmol gap does not exclude methanol poisoning, especially in late presenters. Serum methanol levels confirm the diagnosis, though levels may be undetectable late in the course when severe acidosis is present.
Management begins with prompt stabilization of airway, breathing, and circulation, along with administration of dextrose, naloxone, and thiamine for altered mental status. Further absorption is limited by supportive care, as gastric lavage and activated charcoal have limited benefit due to rapid methanol absorption. The cornerstone of treatment is inhibition of alcohol dehydrogenase to prevent formation of toxic metabolites. Fomepizole is the preferred antidote and should be initiated promptly when methanol ingestion is suspected, even before serum levels return. Ethanol infusion is an alternative when fomepizole is unavailable but is associated with significant adverse effects and requires close monitoring.
Hemodialysis plays a critical role by enhancing elimination of methanol and its metabolites and correcting severe acidosis. Indications include visual symptoms, severe or refractory metabolic acidosis, renal failure, ingestion of large amounts of methanol, or serum methanol levels greater than 25 mg/dL. Hemodialysis is continued until methanol levels fall below 25 mg/dL and acidosis resolves. Adjunctive therapy with folic or folinic acid is recommended to enhance metabolism of formic acid. Sodium bicarbonate is used to correct severe acidosis, with the goal of maintaining a normal serum pH.
Patients with significant exposure require hospital admission, often to the intensive care unit, and transfer to a facility with antidote availability and hemodialysis capability if needed. Asymptomatic patients with low methanol levels, normal acid–base status, and stable electrolytes may be considered for discharge. Psychiatric evaluation is important in cases of intentional ingestion. Early recognition and treatment are essential, as delays greatly increase the risk of blindness and death.
- Published on
KembaraXtra-Medicine – Methanol Poisoning
Methanol is a colorless, volatile liquid that is rapidly absorbed within 30–60 minutes and metabolized by the liver, with a half-life of approximately 4–8 hours. Methanol itself is relatively nontoxic and produces inebriation similar to ethanol. Toxicity results from its metabolites, formaldehyde and formic acid, which inhibit cytochrome oxidase and disrupt cellular respiration. Formic acid is primarily responsible for severe metabolic acidosis, visual toxicity, and mortality, as it is directly toxic to the retina and optic nerve. Methanol is metabolized in three steps: conversion to formaldehyde by alcohol dehydrogenase, rapid conversion of formaldehyde to formic acid by aldehyde dehydrogenase, and folate-dependent degradation of formic acid to carbon dioxide and water. The first and third steps are rate-limiting.
Common sources of methanol exposure include windshield washer fluid, wood alcohol, carburetor cleaners, fuel antifreeze solutions, formalin, gasoline, paint solvents, household cleaners, Sterno cans, moonshine, model airplane fuel, photocopying fluids, and perfumes. Ingestion may be intentional or accidental, and inhalational exposure can occur with solvent abuse.
Clinical manifestations often begin with gastrointestinal symptoms such as anorexia, nausea, vomiting, and abdominal pain. Central nervous system findings include headache, dizziness, confusion, inebriation, seizures, and coma. Ophthalmologic symptoms are characteristic and include blurry or hazy vision, photophobia, “snowfield” vision, central scotomas, and potentially permanent blindness. Patients may present without a clear ingestion history but instead with an unexplained high anion gap metabolic acidosis and elevated osmol gap. On examination, findings may include tachypnea, altered mental status, optic disc hyperemia or pallor, papilledema, and afferent pupillary defects.
Evaluation requires a careful history of all possible ingestions and attention to visual complaints, along with a funduscopic examination. Essential laboratory tests include arterial blood gas analysis, serum electrolytes, glucose, BUN, creatinine, measured serum osmolality, and serum levels of methanol, ethanol, ethylene glycol, and isopropyl alcohol. The anion gap and osmol gap should be calculated. The osmol gap is most useful early in poisoning, as methanol is osmotically active, whereas its toxic metabolites are not. Importantly, a normal osmol gap does not exclude methanol poisoning, especially in late presenters. Serum methanol levels confirm the diagnosis, though levels may be undetectable late in the course when severe acidosis is present.
Management begins with prompt stabilization of airway, breathing, and circulation, along with administration of dextrose, naloxone, and thiamine for altered mental status. Further absorption is limited by supportive care, as gastric lavage and activated charcoal have limited benefit due to rapid methanol absorption. The cornerstone of treatment is inhibition of alcohol dehydrogenase to prevent formation of toxic metabolites. Fomepizole is the preferred antidote and should be initiated promptly when methanol ingestion is suspected, even before serum levels return. Ethanol infusion is an alternative when fomepizole is unavailable but is associated with significant adverse effects and requires close monitoring.
Hemodialysis plays a critical role by enhancing elimination of methanol and its metabolites and correcting severe acidosis. Indications include visual symptoms, severe or refractory metabolic acidosis, renal failure, ingestion of large amounts of methanol, or serum methanol levels greater than 25 mg/dL. Hemodialysis is continued until methanol levels fall below 25 mg/dL and acidosis resolves. Adjunctive therapy with folic or folinic acid is recommended to enhance metabolism of formic acid. Sodium bicarbonate is used to correct severe acidosis, with the goal of maintaining a normal serum pH.
Patients with significant exposure require hospital admission, often to the intensive care unit, and transfer to a facility with antidote availability and hemodialysis capability if needed. Asymptomatic patients with low methanol levels, normal acid–base status, and stable electrolytes may be considered for discharge. Psychiatric evaluation is important in cases of intentional ingestion. Early recognition and treatment are essential, as delays greatly increase the risk of blindness and death.
Methanol is a colorless, volatile liquid that is rapidly absorbed within 30–60 minutes and metabolized by the liver, with a half-life of approximately 4–8 hours. Methanol itself is relatively nontoxic and produces inebriation similar to ethanol. Toxicity results from its metabolites, formaldehyde and formic acid, which inhibit cytochrome oxidase and disrupt cellular respiration. Formic acid is primarily responsible for severe metabolic acidosis, visual toxicity, and mortality, as it is directly toxic to the retina and optic nerve. Methanol is metabolized in three steps: conversion to formaldehyde by alcohol dehydrogenase, rapid conversion of formaldehyde to formic acid by aldehyde dehydrogenase, and folate-dependent degradation of formic acid to carbon dioxide and water. The first and third steps are rate-limiting.
Common sources of methanol exposure include windshield washer fluid, wood alcohol, carburetor cleaners, fuel antifreeze solutions, formalin, gasoline, paint solvents, household cleaners, Sterno cans, moonshine, model airplane fuel, photocopying fluids, and perfumes. Ingestion may be intentional or accidental, and inhalational exposure can occur with solvent abuse.
Clinical manifestations often begin with gastrointestinal symptoms such as anorexia, nausea, vomiting, and abdominal pain. Central nervous system findings include headache, dizziness, confusion, inebriation, seizures, and coma. Ophthalmologic symptoms are characteristic and include blurry or hazy vision, photophobia, “snowfield” vision, central scotomas, and potentially permanent blindness. Patients may present without a clear ingestion history but instead with an unexplained high anion gap metabolic acidosis and elevated osmol gap. On examination, findings may include tachypnea, altered mental status, optic disc hyperemia or pallor, papilledema, and afferent pupillary defects.
Evaluation requires a careful history of all possible ingestions and attention to visual complaints, along with a funduscopic examination. Essential laboratory tests include arterial blood gas analysis, serum electrolytes, glucose, BUN, creatinine, measured serum osmolality, and serum levels of methanol, ethanol, ethylene glycol, and isopropyl alcohol. The anion gap and osmol gap should be calculated. The osmol gap is most useful early in poisoning, as methanol is osmotically active, whereas its toxic metabolites are not. Importantly, a normal osmol gap does not exclude methanol poisoning, especially in late presenters. Serum methanol levels confirm the diagnosis, though levels may be undetectable late in the course when severe acidosis is present.
Management begins with prompt stabilization of airway, breathing, and circulation, along with administration of dextrose, naloxone, and thiamine for altered mental status. Further absorption is limited by supportive care, as gastric lavage and activated charcoal have limited benefit due to rapid methanol absorption. The cornerstone of treatment is inhibition of alcohol dehydrogenase to prevent formation of toxic metabolites. Fomepizole is the preferred antidote and should be initiated promptly when methanol ingestion is suspected, even before serum levels return. Ethanol infusion is an alternative when fomepizole is unavailable but is associated with significant adverse effects and requires close monitoring.
Hemodialysis plays a critical role by enhancing elimination of methanol and its metabolites and correcting severe acidosis. Indications include visual symptoms, severe or refractory metabolic acidosis, renal failure, ingestion of large amounts of methanol, or serum methanol levels greater than 25 mg/dL. Hemodialysis is continued until methanol levels fall below 25 mg/dL and acidosis resolves. Adjunctive therapy with folic or folinic acid is recommended to enhance metabolism of formic acid. Sodium bicarbonate is used to correct severe acidosis, with the goal of maintaining a normal serum pH.
Patients with significant exposure require hospital admission, often to the intensive care unit, and transfer to a facility with antidote availability and hemodialysis capability if needed. Asymptomatic patients with low methanol levels, normal acid–base status, and stable electrolytes may be considered for discharge. Psychiatric evaluation is important in cases of intentional ingestion. Early recognition and treatment are essential, as delays greatly increase the risk of blindness and death.
- Published on
KembaraXtra-Medicine – Mesenteric Ischemia
Mesenteric ischemia is a serious condition caused by decreased or completely occluded blood flow through the mesenteric vessels, leading to ischemia or infarction of the bowel. It may result from arterial obstruction, venous thrombosis, or low-flow states. Although it accounts for only about 1 in 1,000 hospital admissions and 1–2% of admissions for abdominal pain, it carries a very high mortality rate of 60–70%, especially when diagnosis or treatment is delayed beyond 24 hours. Most cases occur in patients older than 50 years.
Acute mesenteric arterial embolism is the most common cause, accounting for approximately half of acute cases. It typically affects elderly patients and most often arises from cardiac sources such as atrial fibrillation, valvular disease, or ventricular thrombus after myocardial infarction. Emboli usually lodge several centimeters distal to the origin of the superior mesenteric artery, sparing proximal bowel segments. Mesenteric arterial thrombosis accounts for about 15% of cases and usually develops from rupture of an atherosclerotic plaque in patients with chronic mesenteric ischemia, often preceded by longstanding postprandial abdominal pain known as intestinal angina.
Mesenteric venous thrombosis represents 5–15% of cases and tends to have a more subacute presentation. It occurs more often in younger patients with underlying hypercoagulable states, including inherited thrombophilias, malignancy, pregnancy, estrogen therapy, sickle cell disease, sepsis, renal failure on dialysis, or recent trauma. Nonocclusive mesenteric ischemia accounts for 20–30% of cases and is associated with low cardiac output states such as congestive heart failure, sepsis, hypotension, hypovolemia, or recent use of vasopressors. This form is associated with poorer survival. Chronic mesenteric ischemia presents with postprandial abdominal pain, food avoidance, and weight loss. Rare causes include mesenteric arterial dissection, median arcuate ligament syndrome, external compression by tumors, and certain medications such as digitalis, ergotamine, cocaine, and vasopressin.
Clinically, acute mesenteric ischemia classically presents with sudden-onset, severe, diffuse abdominal pain that is out of proportion to physical examination findings. Associated symptoms include nausea, vomiting, diarrhea, and occult gastrointestinal bleeding. Elderly patients may present atypically with altered mental status, tachypnea, or tachycardia. As ischemia progresses to infarction, late findings such as peritoneal signs, abdominal distention, and hypoactive bowel sounds may appear.
Laboratory findings are often nonspecific. Leukocytosis is common, metabolic acidosis may be present, and serum lactate is elevated in most patients with advanced disease, correlating with poor prognosis. Imaging plays a crucial role in diagnosis. Plain abdominal radiographs are often normal early but may show pneumatosis intestinalis or pneumobilia in advanced cases. Multidetector CT angiography has become the imaging modality of choice, allowing visualization of mesenteric vessels and bowel wall changes. Angiography, once the gold standard, is now used selectively for both diagnosis and therapeutic intervention.
Management requires rapid recognition and aggressive treatment. Initial stabilization focuses on airway, breathing, and circulation, with prompt fluid resuscitation. Patients should be kept NPO, a nasogastric tube placed for decompression, and electrolyte abnormalities corrected. Broad-spectrum intravenous antibiotics covering bowel flora are essential. Systemic anticoagulation with heparin is recommended unless contraindicated. Vasoconstrictive medications should be avoided when possible, as they may worsen mesenteric perfusion.
Definitive management depends on the underlying cause and severity. Intra-arterial vasodilators such as papaverine may be administered during angiography for vasospasm or nonocclusive ischemia. Thrombolysis or surgical revascularization may be required for arterial occlusion. Any patient with peritoneal signs requires urgent exploratory laparotomy. All patients with mesenteric ischemia require hospital admission and early surgical consultation, as delays in diagnosis and intervention dramatically increase mortality.
Mesenteric ischemia is a serious condition caused by decreased or completely occluded blood flow through the mesenteric vessels, leading to ischemia or infarction of the bowel. It may result from arterial obstruction, venous thrombosis, or low-flow states. Although it accounts for only about 1 in 1,000 hospital admissions and 1–2% of admissions for abdominal pain, it carries a very high mortality rate of 60–70%, especially when diagnosis or treatment is delayed beyond 24 hours. Most cases occur in patients older than 50 years.
Acute mesenteric arterial embolism is the most common cause, accounting for approximately half of acute cases. It typically affects elderly patients and most often arises from cardiac sources such as atrial fibrillation, valvular disease, or ventricular thrombus after myocardial infarction. Emboli usually lodge several centimeters distal to the origin of the superior mesenteric artery, sparing proximal bowel segments. Mesenteric arterial thrombosis accounts for about 15% of cases and usually develops from rupture of an atherosclerotic plaque in patients with chronic mesenteric ischemia, often preceded by longstanding postprandial abdominal pain known as intestinal angina.
Mesenteric venous thrombosis represents 5–15% of cases and tends to have a more subacute presentation. It occurs more often in younger patients with underlying hypercoagulable states, including inherited thrombophilias, malignancy, pregnancy, estrogen therapy, sickle cell disease, sepsis, renal failure on dialysis, or recent trauma. Nonocclusive mesenteric ischemia accounts for 20–30% of cases and is associated with low cardiac output states such as congestive heart failure, sepsis, hypotension, hypovolemia, or recent use of vasopressors. This form is associated with poorer survival. Chronic mesenteric ischemia presents with postprandial abdominal pain, food avoidance, and weight loss. Rare causes include mesenteric arterial dissection, median arcuate ligament syndrome, external compression by tumors, and certain medications such as digitalis, ergotamine, cocaine, and vasopressin.
Clinically, acute mesenteric ischemia classically presents with sudden-onset, severe, diffuse abdominal pain that is out of proportion to physical examination findings. Associated symptoms include nausea, vomiting, diarrhea, and occult gastrointestinal bleeding. Elderly patients may present atypically with altered mental status, tachypnea, or tachycardia. As ischemia progresses to infarction, late findings such as peritoneal signs, abdominal distention, and hypoactive bowel sounds may appear.
Laboratory findings are often nonspecific. Leukocytosis is common, metabolic acidosis may be present, and serum lactate is elevated in most patients with advanced disease, correlating with poor prognosis. Imaging plays a crucial role in diagnosis. Plain abdominal radiographs are often normal early but may show pneumatosis intestinalis or pneumobilia in advanced cases. Multidetector CT angiography has become the imaging modality of choice, allowing visualization of mesenteric vessels and bowel wall changes. Angiography, once the gold standard, is now used selectively for both diagnosis and therapeutic intervention.
Management requires rapid recognition and aggressive treatment. Initial stabilization focuses on airway, breathing, and circulation, with prompt fluid resuscitation. Patients should be kept NPO, a nasogastric tube placed for decompression, and electrolyte abnormalities corrected. Broad-spectrum intravenous antibiotics covering bowel flora are essential. Systemic anticoagulation with heparin is recommended unless contraindicated. Vasoconstrictive medications should be avoided when possible, as they may worsen mesenteric perfusion.
Definitive management depends on the underlying cause and severity. Intra-arterial vasodilators such as papaverine may be administered during angiography for vasospasm or nonocclusive ischemia. Thrombolysis or surgical revascularization may be required for arterial occlusion. Any patient with peritoneal signs requires urgent exploratory laparotomy. All patients with mesenteric ischemia require hospital admission and early surgical consultation, as delays in diagnosis and intervention dramatically increase mortality.
- Published on
KembaraXtra-Medicine – Mercury Poisoning
Mercury poisoning results from exposure to mercury in one of three primary forms: elemental, inorganic salts, or organic mercury. Mercury exerts its toxic effects by reacting with sulfhydryl groups, leading to enzyme inhibition and disruption of cellular membranes. It also binds to phosphoryl, carboxyl, amide, and amine groups of enzymes, further impairing normal cellular function.
Exposure most commonly occurs through inhalation or ingestion, and less frequently through dermal contact. Occupational and environmental exposures are well recognized and include industries such as chlorine and caustic soda manufacturing, dentistry, photography, taxidermy, mercury mining, and the production of thermometers, batteries, lamps, plastics, paints, pigments, fireworks, and explosives. Contaminated seafood is a major source of organic mercury exposure in the general population.
The clinical presentation varies depending on the form of mercury involved. Elemental mercury exposure most often occurs through inhalation, with symptoms developing within hours. Patients may experience cough and dyspnea that can progress to noncardiogenic pulmonary edema, along with metallic taste, excessive salivation, weakness, nausea, diarrhea, fever, headaches, and visual disturbances. Subcutaneous or intravenous exposure may lead to granulomas, abscesses, or pulmonary embolization. Elemental mercury is relatively nontoxic when ingested orally due to poor gastrointestinal absorption.
Inorganic mercurial salt ingestion causes severe caustic gastrointestinal injury. Symptoms include abdominal pain, nausea, vomiting, diarrhea, sore throat, and a metallic taste. Hemorrhagic gastroenteritis with hematemesis and hematochezia may occur, along with acute tubular necrosis and renal failure. Acrodynia, also known as pink disease, is an idiosyncratic reaction seen mainly in children and is characterized by painful extremities, pink discoloration, and desquamation.
Organic mercury exposure, commonly through contaminated seafood, primarily affects the central nervous system. While mild gastrointestinal symptoms may occur acutely, delayed neurologic toxicity predominates and may take weeks to months to appear. Manifestations include paresthesias, ataxia, paralysis, visual field constriction, dysarthria, hearing loss, progressive cognitive decline, and death. Fetal exposure in utero is associated with particularly severe neurologic outcomes.
Diagnosis relies heavily on a detailed exposure history, including occupational risks and recent seafood consumption. Physical examination focuses on identifying respiratory distress, signs of caustic gastrointestinal injury, and neuropsychiatric abnormalities. Laboratory evaluation may reveal renal dysfunction, but mercury levels in blood or urine can be misleading, especially after recent seafood ingestion. Imaging studies such as chest radiographs may show pulmonary edema or metallic deposits, abdominal radiographs can identify ingested mercury, and head CT may demonstrate cerebellar atrophy in chronic cases.
Management begins with immediate removal from the source of exposure and stabilization of airway, breathing, and circulation. Supportive care includes oxygen, intravenous fluids for hypotension, and treatment of altered mental status with dextrose, thiamine, and naloxone when indicated. Elemental mercury inhalation requires close observation for delayed pulmonary edema. Inorganic mercury ingestion warrants aggressive fluid resuscitation and early treatment of shock or renal failure.
Chelation therapy is indicated for symptomatic patients. Dimercaptosuccinic acid (DMSA) is commonly used for organic and some elemental mercury exposures, while dimercaprol (British anti-Lewisite) is preferred for severe inorganic mercury poisoning. Activated charcoal may be used for recent ingestions. Surgical incision and drainage may be required for subcutaneous mercury deposits.
Hospital admission is recommended for patients with respiratory compromise, renal impairment, caustic gastrointestinal injury, or those requiring chelation therapy. Asymptomatic patients exposed to elemental mercury may be discharged after an adequate observation period. Follow-up includes repeat mercury testing, avoidance of seafood before testing, and referral to medical toxicology. Early recognition, thorough exposure history, and appropriate chelation are critical to reducing morbidity and preventing long-term neurologic sequelae.
Mercury poisoning results from exposure to mercury in one of three primary forms: elemental, inorganic salts, or organic mercury. Mercury exerts its toxic effects by reacting with sulfhydryl groups, leading to enzyme inhibition and disruption of cellular membranes. It also binds to phosphoryl, carboxyl, amide, and amine groups of enzymes, further impairing normal cellular function.
Exposure most commonly occurs through inhalation or ingestion, and less frequently through dermal contact. Occupational and environmental exposures are well recognized and include industries such as chlorine and caustic soda manufacturing, dentistry, photography, taxidermy, mercury mining, and the production of thermometers, batteries, lamps, plastics, paints, pigments, fireworks, and explosives. Contaminated seafood is a major source of organic mercury exposure in the general population.
The clinical presentation varies depending on the form of mercury involved. Elemental mercury exposure most often occurs through inhalation, with symptoms developing within hours. Patients may experience cough and dyspnea that can progress to noncardiogenic pulmonary edema, along with metallic taste, excessive salivation, weakness, nausea, diarrhea, fever, headaches, and visual disturbances. Subcutaneous or intravenous exposure may lead to granulomas, abscesses, or pulmonary embolization. Elemental mercury is relatively nontoxic when ingested orally due to poor gastrointestinal absorption.
Inorganic mercurial salt ingestion causes severe caustic gastrointestinal injury. Symptoms include abdominal pain, nausea, vomiting, diarrhea, sore throat, and a metallic taste. Hemorrhagic gastroenteritis with hematemesis and hematochezia may occur, along with acute tubular necrosis and renal failure. Acrodynia, also known as pink disease, is an idiosyncratic reaction seen mainly in children and is characterized by painful extremities, pink discoloration, and desquamation.
Organic mercury exposure, commonly through contaminated seafood, primarily affects the central nervous system. While mild gastrointestinal symptoms may occur acutely, delayed neurologic toxicity predominates and may take weeks to months to appear. Manifestations include paresthesias, ataxia, paralysis, visual field constriction, dysarthria, hearing loss, progressive cognitive decline, and death. Fetal exposure in utero is associated with particularly severe neurologic outcomes.
Diagnosis relies heavily on a detailed exposure history, including occupational risks and recent seafood consumption. Physical examination focuses on identifying respiratory distress, signs of caustic gastrointestinal injury, and neuropsychiatric abnormalities. Laboratory evaluation may reveal renal dysfunction, but mercury levels in blood or urine can be misleading, especially after recent seafood ingestion. Imaging studies such as chest radiographs may show pulmonary edema or metallic deposits, abdominal radiographs can identify ingested mercury, and head CT may demonstrate cerebellar atrophy in chronic cases.
Management begins with immediate removal from the source of exposure and stabilization of airway, breathing, and circulation. Supportive care includes oxygen, intravenous fluids for hypotension, and treatment of altered mental status with dextrose, thiamine, and naloxone when indicated. Elemental mercury inhalation requires close observation for delayed pulmonary edema. Inorganic mercury ingestion warrants aggressive fluid resuscitation and early treatment of shock or renal failure.
Chelation therapy is indicated for symptomatic patients. Dimercaptosuccinic acid (DMSA) is commonly used for organic and some elemental mercury exposures, while dimercaprol (British anti-Lewisite) is preferred for severe inorganic mercury poisoning. Activated charcoal may be used for recent ingestions. Surgical incision and drainage may be required for subcutaneous mercury deposits.
Hospital admission is recommended for patients with respiratory compromise, renal impairment, caustic gastrointestinal injury, or those requiring chelation therapy. Asymptomatic patients exposed to elemental mercury may be discharged after an adequate observation period. Follow-up includes repeat mercury testing, avoidance of seafood before testing, and referral to medical toxicology. Early recognition, thorough exposure history, and appropriate chelation are critical to reducing morbidity and preventing long-term neurologic sequelae.
- Published on
KembaraXtra-Medicine – Meningococcemia
Meningococcemia is a serious bacterial illness caused by Neisseria meningitidis. It can present in several clinical forms, ranging from mild, self-limited disease to rapidly fatal overwhelming sepsis. Other manifestations include meningococcal meningitis, chronic or occult meningococcemia, septic arthritis, and less commonly localized infections. Transmission occurs through close contact with an infected person or an asymptomatic carrier, with intimate kissing and cigarette smoking recognized as independent risk factors.
The disease is caused by Neisseria meningitidis, a gram-negative diplococcus with multiple serotypes. Although many serotypes exist, most infections are caused by serogroups A, B, C, X, Y, and W135, with serogroup B being the most common in the United States. The organism colonizes the human nasopharynx, the only natural reservoir, and may invade the bloodstream after penetrating nasopharyngeal epithelial cells. Circulating bacteria are normally cleared by the spleen, but meningococci produce a potent endotoxin, lipooligosaccharide, which plays a central role in vascular injury, skin manifestations, adrenal hemorrhage, and circulatory collapse. Carrier rates increase with age, reaching up to 30–40% in young adults, while young children have lower immunity and higher infection risk. Disease incidence peaks in fall and spring and is higher in crowded living conditions such as military barracks and dormitories.
Clinical presentation varies widely. Mild meningococcemia is the most common form and is often preceded by an upper respiratory infection. Patients develop fever, chills, myalgias, arthralgias, and malaise, and the illness may resolve spontaneously over several days. However, this form can progress to meningitis or overwhelming sepsis. Overwhelming meningococcal sepsis occurs in approximately 10% of cases and carries a high mortality rate, with most deaths occurring within the first 48 hours. The onset is abrupt, and early symptoms may appear deceptively mild, including low-grade tachycardia, tachypnea, hypotension, fever, vomiting, headache, rash, and muscle tenderness. Infants may present with lethargy, poor feeding, or a bulging fontanel.
A characteristic rash is a key feature, often beginning as petechiae on the skin, mucous membranes, or conjunctivae, and progressing to purpura and ecchymoses. In severe cases, the rash may coalesce and become necrotic, leading to purpura fulminans. Rapid deterioration may follow, with hypotension, shock, metabolic acidosis, acute respiratory distress syndrome, and disseminated intravascular coagulation. Meningitis may or may not be present. A particularly severe complication is Waterhouse–Friderichsen syndrome, marked by bilateral adrenal hemorrhage, vasomotor collapse, and acute renal failure due to prolonged hypotension.
Chronic meningococcemia is uncommon and presents as a more indolent illness over weeks to months. Patients are often well appearing but experience recurrent fevers, chills, arthralgias, migratory polyarthritis, intermittent painful rashes on the extremities, and sometimes splenomegaly. Meningococcal meningitis presents with headache, fever, neck stiffness, altered mental status, lethargy, or obtundation. Septic arthritis may occur during active bacteremia and typically involves multiple joints with severe pain, swelling, effusion, and restricted movement. Less common manifestations include conjunctivitis, sinusitis, pneumonia, urethritis, salpingitis, prostatitis, myocarditis, and pericarditis.
Diagnosis is primarily clinical and should be suspected in any patient with fever, rash, and rapid clinical deterioration. Importantly, diagnostic evaluation must never delay resuscitation or antibiotic administration. Gram stain and cultures may be obtained from blood, cerebrospinal fluid, joint aspirates, sputum, urine, or scrapings of petechial or papular lesions, which may reveal intracellular or extracellular gram-negative diplococci. Laboratory findings may include leukocytosis early in disease, followed by leukopenia in severe cases, thrombocytopenia in association with purpura or DIC, metabolic acidosis, renal dysfunction, and abnormal coagulation parameters. Polymerase chain reaction testing is particularly useful when antibiotics have already been administered.
Management requires immediate stabilization with strict attention to airway, breathing, and circulation. Droplet precautions should be instituted, and public health authorities notified. Aggressive fluid resuscitation is essential for hypotension, with vasopressors such as dopamine, norepinephrine, or epinephrine if shock persists. Early endotracheal intubation is indicated for severe hypoxia, acidosis, or altered mental status. Empiric intravenous antibiotics must be started promptly, typically with a third-generation cephalosporin, and later tailored once the diagnosis is confirmed. Penicillin remains an option for proven susceptible infections, while chloramphenicol may be used in penicillin-allergic patients.
Supportive care includes management of metabolic acidosis, monitoring of urine output, treatment of DIC with blood products as indicated, and consideration of corticosteroids in select cases, particularly with adrenal involvement. Surgical intervention, including debridement or amputation, may be required for necrotic tissue in severe disease.
All patients with meningococcemia require hospital admission, with intensive care indicated for those with sepsis or shock. Close contacts must receive prompt postexposure prophylaxis, ideally within 24 hours, using agents such as rifampin, ciprofloxacin, or ceftriaxone. Vaccination is recommended for specific high-risk groups and as part of routine adolescent immunization programs.
Key clinical pearls include maintaining a high index of suspicion, notifying public health authorities immediately, and never delaying antibiotic therapy for diagnostic testing. Rapid progression, early shock, and rash should always prompt consideration of meningococcemia, as early treatment is critical to survival.
Meningococcemia is a serious bacterial illness caused by Neisseria meningitidis. It can present in several clinical forms, ranging from mild, self-limited disease to rapidly fatal overwhelming sepsis. Other manifestations include meningococcal meningitis, chronic or occult meningococcemia, septic arthritis, and less commonly localized infections. Transmission occurs through close contact with an infected person or an asymptomatic carrier, with intimate kissing and cigarette smoking recognized as independent risk factors.
The disease is caused by Neisseria meningitidis, a gram-negative diplococcus with multiple serotypes. Although many serotypes exist, most infections are caused by serogroups A, B, C, X, Y, and W135, with serogroup B being the most common in the United States. The organism colonizes the human nasopharynx, the only natural reservoir, and may invade the bloodstream after penetrating nasopharyngeal epithelial cells. Circulating bacteria are normally cleared by the spleen, but meningococci produce a potent endotoxin, lipooligosaccharide, which plays a central role in vascular injury, skin manifestations, adrenal hemorrhage, and circulatory collapse. Carrier rates increase with age, reaching up to 30–40% in young adults, while young children have lower immunity and higher infection risk. Disease incidence peaks in fall and spring and is higher in crowded living conditions such as military barracks and dormitories.
Clinical presentation varies widely. Mild meningococcemia is the most common form and is often preceded by an upper respiratory infection. Patients develop fever, chills, myalgias, arthralgias, and malaise, and the illness may resolve spontaneously over several days. However, this form can progress to meningitis or overwhelming sepsis. Overwhelming meningococcal sepsis occurs in approximately 10% of cases and carries a high mortality rate, with most deaths occurring within the first 48 hours. The onset is abrupt, and early symptoms may appear deceptively mild, including low-grade tachycardia, tachypnea, hypotension, fever, vomiting, headache, rash, and muscle tenderness. Infants may present with lethargy, poor feeding, or a bulging fontanel.
A characteristic rash is a key feature, often beginning as petechiae on the skin, mucous membranes, or conjunctivae, and progressing to purpura and ecchymoses. In severe cases, the rash may coalesce and become necrotic, leading to purpura fulminans. Rapid deterioration may follow, with hypotension, shock, metabolic acidosis, acute respiratory distress syndrome, and disseminated intravascular coagulation. Meningitis may or may not be present. A particularly severe complication is Waterhouse–Friderichsen syndrome, marked by bilateral adrenal hemorrhage, vasomotor collapse, and acute renal failure due to prolonged hypotension.
Chronic meningococcemia is uncommon and presents as a more indolent illness over weeks to months. Patients are often well appearing but experience recurrent fevers, chills, arthralgias, migratory polyarthritis, intermittent painful rashes on the extremities, and sometimes splenomegaly. Meningococcal meningitis presents with headache, fever, neck stiffness, altered mental status, lethargy, or obtundation. Septic arthritis may occur during active bacteremia and typically involves multiple joints with severe pain, swelling, effusion, and restricted movement. Less common manifestations include conjunctivitis, sinusitis, pneumonia, urethritis, salpingitis, prostatitis, myocarditis, and pericarditis.
Diagnosis is primarily clinical and should be suspected in any patient with fever, rash, and rapid clinical deterioration. Importantly, diagnostic evaluation must never delay resuscitation or antibiotic administration. Gram stain and cultures may be obtained from blood, cerebrospinal fluid, joint aspirates, sputum, urine, or scrapings of petechial or papular lesions, which may reveal intracellular or extracellular gram-negative diplococci. Laboratory findings may include leukocytosis early in disease, followed by leukopenia in severe cases, thrombocytopenia in association with purpura or DIC, metabolic acidosis, renal dysfunction, and abnormal coagulation parameters. Polymerase chain reaction testing is particularly useful when antibiotics have already been administered.
Management requires immediate stabilization with strict attention to airway, breathing, and circulation. Droplet precautions should be instituted, and public health authorities notified. Aggressive fluid resuscitation is essential for hypotension, with vasopressors such as dopamine, norepinephrine, or epinephrine if shock persists. Early endotracheal intubation is indicated for severe hypoxia, acidosis, or altered mental status. Empiric intravenous antibiotics must be started promptly, typically with a third-generation cephalosporin, and later tailored once the diagnosis is confirmed. Penicillin remains an option for proven susceptible infections, while chloramphenicol may be used in penicillin-allergic patients.
Supportive care includes management of metabolic acidosis, monitoring of urine output, treatment of DIC with blood products as indicated, and consideration of corticosteroids in select cases, particularly with adrenal involvement. Surgical intervention, including debridement or amputation, may be required for necrotic tissue in severe disease.
All patients with meningococcemia require hospital admission, with intensive care indicated for those with sepsis or shock. Close contacts must receive prompt postexposure prophylaxis, ideally within 24 hours, using agents such as rifampin, ciprofloxacin, or ceftriaxone. Vaccination is recommended for specific high-risk groups and as part of routine adolescent immunization programs.
Key clinical pearls include maintaining a high index of suspicion, notifying public health authorities immediately, and never delaying antibiotic therapy for diagnostic testing. Rapid progression, early shock, and rash should always prompt consideration of meningococcemia, as early treatment is critical to survival.
- Published on
KembaraXtra – Medicine – Ménière Disease
Ménière disease is a chronic disorder of the inner ear characterized by recurrent, spontaneous episodes of vertigo accompanied by sensorineural hearing loss, tinnitus, and a sensation of aural fullness. The condition most commonly affects one ear, although bilateral involvement may occur in up to 40% of patients. The estimated incidence is approximately 15 per 100,000 people in the United States, with a slight female predominance. Although Ménière disease can occur at any age, it most frequently presents between 40 and 60 years of age. While benign and nonfatal, it can lead to significant morbidity due to the unpredictability and severity of symptoms.
The etiology of Ménière disease is idiopathic, with endolymphatic hydrops considered the primary underlying mechanism. This condition results from impaired drainage of endolymph from the endolymphatic sac and duct, leading to increased pressure within the endolymphatic system. Elevated pressure may cause rupture of the membrane separating potassium-rich endolymph from potassium-poor perilymph, resulting in abnormal stimulation and transient dysfunction of vestibular and cochlear nerve receptors. Additional proposed contributors include structural abnormalities of the endolymphatic system, autoimmune processes, genetic predisposition, remote viral injury, and ischemia of the inner ear. It is important to distinguish Ménière disease from secondary Ménière syndrome caused by conditions such as thyroid disease, syphilis, autoimmune inner ear disease, or medication effects.
Diagnosis is based primarily on clinical features supported by neurotologic evaluation. Definitive diagnosis requires histopathologic confirmation and therefore can only be made postmortem, though modern MRI techniques may provide supportive evidence. Diagnostic criteria include at least two spontaneous episodes of vertigo lasting 20 minutes or longer, at least one documented episode of sensorineural hearing loss on audiometric testing, and the presence of tinnitus or aural fullness in the affected ear. Based on the completeness of findings, cases are categorized as definite, probable, or possible Ménière disease.
Patients typically present with the classic tetrad of vertigo, hearing loss, tinnitus, and aural fullness. Vertigo attacks last from minutes to hours and are frequently associated with nausea and vomiting. Hearing loss is sensorineural, fluctuating, and progressive, often initially affecting low frequencies before potentially involving all frequencies over time. Tinnitus is commonly low-pitched and described as roaring, while aural fullness is perceived as pressure or congestion in the affected ear. Attacks usually reach peak intensity rapidly and resolve gradually, leaving patients fatigued and unsteady for hours to days. Some individuals may be asymptomatic between episodes, while others experience persistent imbalance. Sudden drop attacks without loss of consciousness may also occur.
Physical examination findings vary depending on whether the patient is evaluated during or between attacks. During acute episodes, patients may appear pale, diaphoretic, and distressed. Horizontal nystagmus and impaired hearing are commonly observed. Tuning fork testing often reveals lateralization away from the affected ear on Weber testing, with preserved air conduction on Rinne testing. Romberg testing may demonstrate postural instability, particularly with eyes closed. A thorough neurologic and otologic examination is essential to exclude central nervous system pathology or alternative peripheral ear disorders.
The essential evaluation includes a detailed history and complete neurologic examination. Neuroimaging is warranted when central causes of vertigo are suspected or when focal neurologic deficits are present, particularly in patients with new unilateral hearing loss. Audiometric testing is critical for documenting sensorineural hearing loss, and additional vestibular studies such as caloric testing, electronystagmography, or electrocochleography are typically performed in the outpatient setting. Laboratory investigations are reserved for suspected systemic or secondary causes.
Management in the acute setting focuses on symptom control and exclusion of life-threatening conditions such as stroke. Patients should be protected from falls and maintained in a comfortable position. Intravenous fluids are indicated for dehydration due to vomiting. Benzodiazepines and antiemetics are first-line therapies for acute vertigo and nausea, with antihistamines used as adjuncts. Long-term management aims to reduce the frequency and severity of attacks through dietary sodium restriction, avoidance of triggers such as caffeine and alcohol, diuretics, corticosteroids, and selected transtympanic therapies. Surgical interventions are reserved for patients with severe, refractory disease.
Disposition depends on symptom severity and response to treatment. Admission is indicated for patients with intractable vertigo, persistent vomiting, dehydration, or inability to ambulate safely. Most patients can be discharged once symptoms are controlled, oral intake is tolerated, gait is stable, and neurologic examination is normal. Discharged patients should receive fall precautions and counseling to avoid driving or hazardous activities until symptoms have resolved and sedating medications have been discontinued. Outpatient follow-up with otolaryngology, otology, or neurology is recommended for further evaluation, audiometry, and long-term management.
- Published on
Emergency and Acute Medicine – Meningitis
Basics description
Meningitis is an infection of the central nervous system characterized by inflammation of the leptomeninges and an increased white blood cell count in the cerebrospinal fluid (CSF). It commonly presents with fever, headache, neck stiffness, and altered mental status, although manifestations vary by age and immune status.
Etiology
Meningitis may be bacterial, viral, fungal, or noninfectious in origin. In neonates, common bacterial causes include group B Streptococcus, Escherichia coli, other enteric bacilli, and Listeria monocytogenes. In children and adults, Streptococcus pneumoniae and Neisseria meningitidis predominate, while elderly patients and those with alcoholism are at increased risk for pneumococcal infection, gram-negative bacilli, and Listeria. Neurosurgical patients are more likely to develop infections due to staphylococcal or gram-negative organisms. Immunocompromised patients, including those with AIDS, may develop tuberculosis, fungal, or syphilitic meningitis in addition to typical pathogens. Viral meningitis is common and often less severe, while chemical, drug-induced, or toxin-related meningitis is rare.
Clinical presentation
Typical symptoms include fever, headache, photophobia, and neck stiffness. Kernig and Brudzinski signs may be present but are neither sensitive nor specific. Patients may also develop altered mental status, seizures, focal neurologic deficits, papilledema, or a petechial or purpuric rash suggestive of meningococcal disease. Associated infections such as sinusitis, otitis media, or pneumonia may provide clues to the source.
Infants and young children often present atypically, with fever or hypothermia, lethargy, poor feeding, vomiting, respiratory distress, apnea, cyanosis, hypotonia, or a bulging fontanelle. Classic meningeal signs are frequently absent in children under one year of age. Elderly or immunocompromised patients may present primarily with confusion and fewer classic symptoms.
Essential workup
Management should begin immediately when meningitis is suspected. Blood cultures should be obtained promptly, followed by empiric antimicrobial therapy without delay, especially if the patient is unstable. Lumbar puncture is recommended for all patients with suspected meningitis unless contraindicated. Neuroimaging prior to lumbar puncture is reserved for patients at risk for herniation, including those with immunodeficiency, recent seizures, focal neurologic deficits, altered consciousness, papilledema, a history of central nervous system disease, or age over 60 years.
CSF analysis includes cell count and differential, glucose, protein, Gram stain, and culture, with additional studies added as clinically indicated. Elevated opening pressure may be present. Typical bacterial meningitis is associated with low CSF glucose, elevated protein, and a high white blood cell count with neutrophil predominance, although early disease may show fewer abnormalities.
Diagnostic tests and interpretation
Laboratory evaluation includes blood cultures, complete blood count, electrolytes, renal function tests, coagulation studies, and serum glucose for comparison with CSF glucose. Imaging such as head CT is used selectively to assess for contraindications to lumbar puncture or complications. Chest radiography may identify pneumonia or tuberculosis when suspected. Polymerase chain reaction testing and antigen detection may assist in identifying viral or bacterial pathogens when cultures are nondiagnostic.
Differential diagnosis
Conditions that may mimic meningitis include encephalitis, intracranial abscess, epidural or spinal abscess, febrile seizures, intracranial hemorrhage, stroke, systemic or central nervous system lupus, malignancy, venous sinus thrombosis, trauma, and metabolic or toxic encephalopathies.
Treatment and emergency management
Initial management focuses on airway, breathing, and circulation, seizure control, and isolation when appropriate. Empiric intravenous antibiotics should be administered as soon as possible, ideally after blood cultures but without delaying treatment for imaging or lumbar puncture. Antimicrobial regimens are selected based on patient age, immune status, and risk factors, with coverage for likely organisms. Vancomycin is added when resistant pneumococcal infection is a concern, and ampicillin is included in older adults and immunocompromised patients for Listeria coverage. Acyclovir should be started when herpes simplex encephalitis is suspected.
Adjunctive corticosteroids may reduce neurologic complications in selected patients, particularly those with pneumococcal meningitis, and should be given before or with the first dose of antibiotics when indicated.
Disposition and follow-up
Hospital admission is required for all patients with known or suspected bacterial meningitis, immunocompromised patients, and any toxic-appearing individual. Discharge from the emergency department is reserved for carefully selected patients with confirmed viral meningitis, stable clinical status, reliable follow-up, and clear discharge instructions coordinated with primary care.
Pearls and pitfalls
Meningitis rarely presents as a simple febrile seizure in children. Delayed recognition or treatment can lead to severe neurologic injury or death, making early empiric therapy essential. When clinical suspicion is high, treatment should never be postponed while awaiting diagnostic confirmation.
- Published on
KembaraXtra-Medicine – Marine Envenomation
Marine envenomation refers to poisoning caused by the sting or bite of marine vertebrate or invertebrate species. These injuries occur in a wide variety of aquatic environments and range from mild local reactions to rapidly fatal systemic toxicity. Common causative organisms include sponges, jellyfish, echinoderms, mollusks, fish, and sea snakes, each producing distinct clinical syndromes based on venom type and mechanism of delivery.
The etiology varies by species. Sponges contain sharp spicules coated with irritants that penetrate the skin and cause dermatitis. Jellyfish and other cnidarians possess nematocysts that eject hollow toxin-filled tubules on contact; box jellyfish are particularly dangerous and can cause death within minutes. Starfish and sea urchins deliver venom through rigid or hollow spines, while sea cucumbers secrete holothurin, a toxin capable of causing severe ocular injury. Cone shells inject potent neurotoxic peptides through dart-like teeth that interfere with neuromuscular transmission. Stingrays, the most common cause of marine envenomation, inject venom via serrated tail spines. Scorpion fish, including lionfish and stonefish, possess dorsal spines with neurotoxic venom, and catfish envenomate through dorsal and pectoral spines. Sea snakes inject highly neurotoxic venom through hollow fangs, leading to neuromuscular blockade.
Clinical presentation depends on the organism involved and the severity of envenomation. Sponge exposure typically causes delayed itching, burning, local swelling, and systemic symptoms such as fever, malaise, nausea, and muscle cramps, with possible skin desquamation weeks later. Jellyfish stings cause immediate pain, burning, wheals, and blistering, while severe cases may progress to neurologic deficits, cardiovascular collapse, respiratory failure, gastrointestinal symptoms, or ocular injury. Echinoderm injuries range from localized pain and edema with starfish to intense pain, muscle aches, hypotension, and respiratory distress with multiple sea urchin stings. Sea cucumber exposure often causes mild dermatitis but may result in severe corneal injury and blindness.
Mollusk envenomation, particularly from cone shells, begins with sharp puncture pain and paresthesias that may progress to paralysis, respiratory failure, dysphagia, syncope, or disseminated intravascular coagulation. Stingray injuries present as puncture wounds or lacerations with severe pain, edema, bleeding, and possible tissue necrosis, along with systemic symptoms such as nausea, hypotension, dysrhythmias, seizures, and paralysis. Scorpion fish stings cause intense pain lasting hours and may be accompanied by fever, delirium, seizures, and hypertension. Catfish injuries result in local pain, swelling, bleeding, muscle spasms, and neuropathic symptoms. Sea snake bites are often initially painless but progress within minutes to hours to muscle pain, paralysis, trismus, dysphagia, renal failure, and coma, with high mortality if untreated.
Diagnosis relies primarily on a thorough history and physical examination. Important historical elements include the time and location of exposure, type of water, activity at the time of injury, geographic location, symptom onset, and mental status changes. Physical examination focuses on airway stability, vital signs, neurologic status, cardiopulmonary findings, and careful inspection of wounds for retained foreign bodies, cellulitis, or blistering. Laboratory evaluation may include complete blood count, electrolytes, renal and liver function tests, urinalysis, and arterial blood gases in severe cases. Soft tissue radiographs may be useful to identify retained spines or foreign bodies.
Initial management begins in the prehospital setting with removal from the water, airway and breathing support, hemorrhage control, and avoidance of further venom activation. In the emergency setting, stabilization of airway, breathing, and circulation is the priority, with intravenous access and fluid resuscitation as needed. Clinicians must be prepared to manage anaphylaxis, respiratory failure, and severe pain. General measures include tetanus prophylaxis, antihistamines for pruritus, corticosteroids for severe reactions, narcotic analgesia, and antibiotics for deep, contaminated, or high-risk wounds.
Definitive treatment is species-specific. Spicule injuries from sponges are managed by drying the skin, removing spicules with adhesive tape, and soaking with vinegar or isopropyl alcohol. Jellyfish stings should be rinsed with seawater, treated with vinegar to inactivate nematocysts, and carefully debrided; box jellyfish stings require urgent antivenom. Echinoderm, cone shell, stingray, scorpion fish, and catfish injuries are treated with nonscalding hot water immersion for pain relief and venom inactivation, along with wound exploration and spine removal. Stonefish and sea snake envenomations require specific antivenoms, and sea snake bites necessitate early immobilization, pressure bandaging, and preparation for assisted ventilation.
Patients with systemic toxicity, severe local injury, or need for antivenom require hospital admission. Those without systemic symptoms after adequate observation may be discharged with wound care instructions and follow-up. Key clinical pearls include recognizing that most marine toxins are inactivated by heat or acidic solutions, avoiding fresh water on jellyfish stings, and securing antivenom early when indicated, as supplies are limited and delays can be fatal.
Marine envenomation refers to poisoning caused by the sting or bite of marine vertebrate or invertebrate species. These injuries occur in a wide variety of aquatic environments and range from mild local reactions to rapidly fatal systemic toxicity. Common causative organisms include sponges, jellyfish, echinoderms, mollusks, fish, and sea snakes, each producing distinct clinical syndromes based on venom type and mechanism of delivery.
The etiology varies by species. Sponges contain sharp spicules coated with irritants that penetrate the skin and cause dermatitis. Jellyfish and other cnidarians possess nematocysts that eject hollow toxin-filled tubules on contact; box jellyfish are particularly dangerous and can cause death within minutes. Starfish and sea urchins deliver venom through rigid or hollow spines, while sea cucumbers secrete holothurin, a toxin capable of causing severe ocular injury. Cone shells inject potent neurotoxic peptides through dart-like teeth that interfere with neuromuscular transmission. Stingrays, the most common cause of marine envenomation, inject venom via serrated tail spines. Scorpion fish, including lionfish and stonefish, possess dorsal spines with neurotoxic venom, and catfish envenomate through dorsal and pectoral spines. Sea snakes inject highly neurotoxic venom through hollow fangs, leading to neuromuscular blockade.
Clinical presentation depends on the organism involved and the severity of envenomation. Sponge exposure typically causes delayed itching, burning, local swelling, and systemic symptoms such as fever, malaise, nausea, and muscle cramps, with possible skin desquamation weeks later. Jellyfish stings cause immediate pain, burning, wheals, and blistering, while severe cases may progress to neurologic deficits, cardiovascular collapse, respiratory failure, gastrointestinal symptoms, or ocular injury. Echinoderm injuries range from localized pain and edema with starfish to intense pain, muscle aches, hypotension, and respiratory distress with multiple sea urchin stings. Sea cucumber exposure often causes mild dermatitis but may result in severe corneal injury and blindness.
Mollusk envenomation, particularly from cone shells, begins with sharp puncture pain and paresthesias that may progress to paralysis, respiratory failure, dysphagia, syncope, or disseminated intravascular coagulation. Stingray injuries present as puncture wounds or lacerations with severe pain, edema, bleeding, and possible tissue necrosis, along with systemic symptoms such as nausea, hypotension, dysrhythmias, seizures, and paralysis. Scorpion fish stings cause intense pain lasting hours and may be accompanied by fever, delirium, seizures, and hypertension. Catfish injuries result in local pain, swelling, bleeding, muscle spasms, and neuropathic symptoms. Sea snake bites are often initially painless but progress within minutes to hours to muscle pain, paralysis, trismus, dysphagia, renal failure, and coma, with high mortality if untreated.
Diagnosis relies primarily on a thorough history and physical examination. Important historical elements include the time and location of exposure, type of water, activity at the time of injury, geographic location, symptom onset, and mental status changes. Physical examination focuses on airway stability, vital signs, neurologic status, cardiopulmonary findings, and careful inspection of wounds for retained foreign bodies, cellulitis, or blistering. Laboratory evaluation may include complete blood count, electrolytes, renal and liver function tests, urinalysis, and arterial blood gases in severe cases. Soft tissue radiographs may be useful to identify retained spines or foreign bodies.
Initial management begins in the prehospital setting with removal from the water, airway and breathing support, hemorrhage control, and avoidance of further venom activation. In the emergency setting, stabilization of airway, breathing, and circulation is the priority, with intravenous access and fluid resuscitation as needed. Clinicians must be prepared to manage anaphylaxis, respiratory failure, and severe pain. General measures include tetanus prophylaxis, antihistamines for pruritus, corticosteroids for severe reactions, narcotic analgesia, and antibiotics for deep, contaminated, or high-risk wounds.
Definitive treatment is species-specific. Spicule injuries from sponges are managed by drying the skin, removing spicules with adhesive tape, and soaking with vinegar or isopropyl alcohol. Jellyfish stings should be rinsed with seawater, treated with vinegar to inactivate nematocysts, and carefully debrided; box jellyfish stings require urgent antivenom. Echinoderm, cone shell, stingray, scorpion fish, and catfish injuries are treated with nonscalding hot water immersion for pain relief and venom inactivation, along with wound exploration and spine removal. Stonefish and sea snake envenomations require specific antivenoms, and sea snake bites necessitate early immobilization, pressure bandaging, and preparation for assisted ventilation.
Patients with systemic toxicity, severe local injury, or need for antivenom require hospital admission. Those without systemic symptoms after adequate observation may be discharged with wound care instructions and follow-up. Key clinical pearls include recognizing that most marine toxins are inactivated by heat or acidic solutions, avoiding fresh water on jellyfish stings, and securing antivenom early when indicated, as supplies are limited and delays can be fatal.
